UK markets close in 4 hours 49 minutes

Spyre Therapeutics, Inc. (SYRE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.99-1.26 (-3.68%)
At close: 04:00PM EDT
32.99 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close34.25
Open34.17
Bid32.85 x 100
Ask33.29 x 100
Day's range32.25 - 34.48
52-week range2.65 - 47.97
Volume203,860
Avg. volume498,950
Market cap1.209B
Beta (5Y monthly)2.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.00
  • PR Newswire

    Spyre Therapeutics Announces Grants of Inducement Awards

    Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 90,100 shares of common stock of Spyre to 3 non-executive emplo

  • PR Newswire

    Spyre Therapeutics Announces $180 Million Private Placement

    Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fee

  • PR Newswire

    Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced its fourth quarter and full year 2023 financial results and provided program and corporate updates.